LOTTE BIOLOGICS and Asimov Announce Partnership
Complete the form below to unlock access to ALL audio articles.
Asimov and LOTTE BIOLOGICS announced a strategic partnership focused on accelerating cell line development and scaling to GMP manufacturing, having demonstrated successful scale-up.
This collaboration combines Asimov's advanced CHO Edge cell line development platform with LOTTE BIOLOGICS' robust large-scale manufacturing services, significantly increasing efficiency and speed from development to production for therapeutic developers.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREEAlec Nielsen, Asimov co-founder and CEO, said: “We’re delighted to be directly integrating with LOTTE BIOLOGICS’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell line development to large-scale GMP production, and drastically shorten their development cycles.”
James Park, LOTTE BIOLOGICS CEO, commented: “We believe this agreement will unlock the full potential of both companies’ strengths. By combining Asimov’s cutting-edge technology with LOTTE BIOLOGICS’ manufacturing excellence, we will not only deliver unparalleled services to our customers but also drive innovation in the biopharmaceutical industry. Ultimately, our goal is to make a meaningful impact on patients’ lives, and we will continue striving to be a company that contributes to a healthier future for all.”
